Insmed (INSM) Long-Term Investments (2021 - 2022)

Insmed (INSM) posted Long-Term Investments of $9.8 million for Q2 2022, down 66.96% on a QoQ basis from $29.6 million in Q1 2022.

Analysis

Insmed (INSM) Long-Term Investments (2021 - 2022) Analysis & Trends

Insmed has reported Long-Term Investments for 2 years, with the latest figure at $9.8 million in Q2 2022.

On a quarterly basis, Long-Term Investments changed N/A year-over-year to $9.8 million in Q2 2022; TTM through Jun 2022 was $9.8 million, a N/A change from a year earlier, with the FY2021 full-year figure at $50.0 million, changed N/A from the prior year.
Long-Term Investments was $9.8 million for Q2 2022 at Insmed, down from $29.6 million in the prior quarter.
The five-year high for Long-Term Investments was $50.0 million in Q4 2021, with the low at $9.8 million in Q2 2022.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Amgen	236.37 Bn	222.38 Bn	7.24 Bn	-
2	Gilead Sciences	187.38 Bn	184.12 Bn	6.22 Bn	-
3	Vertex Pharmaceuticals	138.36 Bn	130.51 Bn	2.84 Bn	5.79 Bn
4	Regeneron Pharmaceuticals	85.09 Bn	77.10 Bn	3.93 Bn	9.83 Bn
5	Argenx Se	63.93 Bn	58.75 Bn	1.37 Bn	-4.00 Mn
6	Moderna	58.07 Bn	52.94 Bn	52.00 Mn	1.77 Bn
7	Alnylam Pharmaceuticals	35.59 Bn	32.28 Bn	992.69 Mn	22.17 Mn
8	Biogen	32.63 Bn	31.34 Bn	1.96 Bn	-
9	Insmed	27.57 Bn	26.41 Bn	358.27 Mn	-
10	BioNTech SE	26.24 Bn	12.58 Bn	10.00 Mn	-

Historic Data

Download Data